Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Granulate for the formulation of orodispersible tablets

a technology of granulate and orodispersible tablets, which is applied in the direction of biocide, plant growth regulators, pharmaceutical non-active ingredients, etc., can solve the problems of increasing the mass of the tablet restrictor, slowing down the disintegration, and the disintegration function of the disintegrant, so as to achieve less pressure, good mechanical properties, and greater porosity

Inactive Publication Date: 2010-10-14
E PHARM TRENTO SPA
View PDF8 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0014]The Applicant has found that a granulate comprising mannitol and sorbitol in a specific weight ratio makes it possible to manufacture OD tablets which disintegrate rapidly, in times less than 30 seconds, in contact with saliva in the oral cavity, with good palatability.
[0020]In addition to this, the increase in tablet size makes it possible to apply less pressure per unit surface area during the compression step, and as a consequence to obtain greater porosity.
[0023]The Applicant has found that use of the granulate according to this invention makes it possible to obtain tablets with a high compressibility index. The compressibility index is given by the ratio between the hardness of the tablet and the compression force. For the same compression force the tablets obtained using the granulate according to this invention have greater hardness and lower density. Greater hardness imparts the necessary strength upon the tablet to withstand mechanical stresses during the processes of production and packaging without breaking up. Lower density imparts greater porosity on the tablet and therefore a greater rate of disintegration because water penetrates within the OD tablet more quickly.

Problems solved by technology

Taking a time of 20-30 seconds as a commercially acceptable value for the definition of fast disintegration, no tablets having a mass of more than 600 mg are found on the market because increased mass makes it difficult for saliva to penetrate the tablet and therefore inhibits the function of the disintegrants, with consequent slowing of disintegration.
However, the presence of a disintegrant, which is necessary for the disintegration of conventional OD tablets, has two disadvantages—on the one hand it increases the mass of the tablet restricting the possibility of adding the active ingredient in larger doses, and on the other it absorbs saliva, leaving a dry feeling in the oral cavity.
The production of OD tablets requires suitably designed manufacturing units because of the poor mechanical properties of the tablets.
Lubricants have to be added to increase the compressibility and flowability of the powders, but there is the disadvantage that these excipients reduce the wettability of the tablet and therefore the rate of disintegration.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Granulate for the formulation of orodispersible tablets

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0077]A mixture of powdered mannitol (average size less than 100 μm) and powdered sorbitol (average size between 200 μm and 250 μm) in a weight ratio of 9:1 was used to prepare the granulate using different granulation methods.

[0078]Using the dry granulation technique, the mixture was first compacted by a tablet press into slugs having a diameter of approximately 20-30 mm. Using different compression forces, slugs TA, TB, TC having respective hardness of 20N, 50N and 120N were obtained. The slugs were then broken up using an oscillating granulator and sieved through a 1000 μm sieve. Granulates A, B and C obtained from slugs TA, TB, TC respectively had the average sizes and densities indicated in Table 1.

[0079]Using the wet granulation technique, the mixture was wet granulated with purified water in an Erweka AR400 granulator. The paste was dried on a fluidised bed and sieved through a 1000 μm mesh. Granulate D had an average size and density as indicated in Table 1 below.

[0080]Using...

example 2

[0083]Granulate E according to this invention was compared with a series of commercial excipients ready for compression. The comparison was made by comparing a series of tablets as described in Example 1 and measuring the resulting hardness of each tablet obtained. The results are summarised in Table 3 below.

TABLE 3ExcipientHardness (N)CIGranulate E3004.62Xylitab 200 (Danisco)2854.38Sorbitol (Roquette)2453.77Maltodextrin2153.31Isomalt (Diamalt)2143.29Emdex (Mendell)2123.26Ercawax 4000 (Erca)1963.02Pearlitol (Roquette)1632.51Lactose DC1051.62Microtal (T&L)921.42Saccharose751.15Fructose500.77Citric acid450.69

[0084]The data in Table 3 showed that granulate E has the best compressibility index (CI) in comparison with the excipients known in the art.

example 3

[0085]Granulate E according to this invention was prepared following the procedure described in Example 1, varying the process conditions (temperature and humidity) of the air. The results are summarised in Table 4 below.

TABLE 4Temperature (° C.)Relative humidity (%)Result800.1Non-conforming product -product melted and turnedto yellow700.1Optimum product -moisture content 0.1% after20 minutes drying500.1Non-conforming product -product moisture content0.25% after 50 minutesdrying (long)701Conforming product -product moisture content0.20% after 60 minutesdrying (long)7010Conforming product -product moisture content0.20% after 70 minutesdrying (long)7025Non-conforming product -product moisture content0.25% after 70 minutesdrying (long)

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Login to View More

Abstract

This invention relates to a granulate comprising mannitol and sorbitol in a weight ratio of between 70:30 and 97:3. This invention also relates to the use of the said granulate in the preparation of orodispersible tablets, to the orodispersible tablets obtained with the said granulate and to a process of production for obtaining the said granulate.

Description

FIELD OF THE INVENTION[0001]This invention relates to a granulate for the formulation of orodispersible tablets, in particular the formulation of orodispersible tablets comprising pharmaceutical or nutritional active ingredients.[0002]In particular this invention relates to a granulate comprising mannitol and sorbitol in a weight ratio between 70:30 and 97:3. This invention also relates to the use of the said granulate in the preparation of orodispersible tablets, to orodispersible tablets obtained using the said granulate and to a production process for obtaining the said granulate.[0003]The orodispersible tablets obtained using the granulate according to this invention have high porosity and may comprise a high content of the active ingredient in comparison with the orodispersible tablets known in the art.STATE OF THE ART[0004]Orodispersible (OD) tablets are tablets taken orally which rapidly disintegrate in the mouth through the effect of the solvent action of saliva and the mech...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/16A61K47/10A61P1/08A61P29/00A61P37/08A61P25/22
CPCA61K9/0056A61K47/26A61K9/2018A61K9/1623A61P1/08A61P25/22A61P29/00A61P37/08B01J2/16
Inventor ROSSI, MASSIMILIANOCATALANO, RICCARDOBOSCHETTI, SILVIAANDREATTA, PAOLO
Owner E PHARM TRENTO SPA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com